Gilead developing inhaled remdesivir usable outside of hospitals

Source

Gilead Sciences is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after trials showed moderate effectiveness for the drug given by infusion.

Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better.

For critically ill patients, Roche and Eli Lilly are testing drugs in combination with remdesivir.

Gilead is also seeking to treat the virus earlier. Other antivirals, like influenza pill Tamiflu, work best when given as early as possible after someone becomes infected.

Gilead in a statement on Monday said it is looking at ways to use remdesivir earlier in the course of disease, including via alternate formulations. The company confirmed in an e-mail that it is researching an inhaled version, but declined further comment.

Company executives such as Chief Medical Officer Merdad Parsey and Chief Financial Officer Andrew Dickinson have been doing interviews with Wall Street analysts in recent weeks to discuss the plans, which are in early stages.

They have said that in the longer term, the company is exploring a subcutaneous injection formulation of remdesivir, as well as dry powder versions to be inhaled. Remdesivir cannot be given as a pill because it has a chemical makeup that would degrade in the liver, and the intravenous formulation is only used by hospitals.

In the short term, Gilead is studying how its existing IV formulation of remdesivir can be diluted for use with a nebulizer — a drug delivery device used to administer medication in the form of a mist inhaled into the lungs.

The idea is that a nebulizer would make remdesivir more directly available to upper airway and lung tissue as the coronavirus is known to attack the lungs. It would also allow for early treatment of coronavirus patients who are not hospitalized.

“People look forward to an inhaled formulation in time,” but development is in the very early stages, said Jefferies analyst Michael Yee, adding that demand may be limited as many people infected with the virus require minimal treatment.

He said Gilead is building up its capacity to supply remdesivir and has begun talking to governments around the world about commercial pricing.

Gilead on Monday reported trial results showing that IV remdesivir provided a modest benefit for hospitalized patients with moderate COVID-19 compared to standard care.

nypost.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related News

Gov. Cuomo creates user-unfriendly ‘Reopening New York Metropolis’ on-line information

Source As if re-opening after being shut down for months by a pandemic wasn’t tough sufficient, the governor’s workplace has created a clunky on-line information...

Nick Cordero had stem cell remedy to heal lungs from COVID, spouse reveals

Source Coronavirus-stricken Broadway star Nick Cordero has undergone stem cell remedy to assist enhance his lung well being, his spouse Amanda Kloots revealed. “We have now...

Greatest information but of 2020: Indicators America’s bouncing again quick

Source Simply when it felt just like the nation was utterly falling aside comes nice information: shocking, unprecedented job development together with clear indicators that...

Vaccines group raises $8.8B for immunization plans for poor international locations

Source LONDON – The GAVI vaccines alliance mentioned on Thursday it had raised $8.Eight billion from worldwide donor governments, firms and philanthropic foundations to fund...

Navy provider sidelined by coronavirus again working in Pacific

Source Ten lengthy weeks after a massive coronavirus outbreak sidelined one of many Navy’s signature warships, the usS. Theodore Roosevelt has returned to sea and...